1. Home
  2. SAMG vs RNTX Comparison

SAMG vs RNTX Comparison

Compare SAMG & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Silvercrest Asset Management Group Inc.

SAMG

Silvercrest Asset Management Group Inc.

HOLD

Current Price

$10.18

Market Cap

76.4M

Sector

Finance

ML Signal

HOLD

RNTX

Rein Therapeutics Inc.

HOLD

Current Price

$0.87

Market Cap

65.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SAMG
RNTX
Founded
2002
2001
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
76.4M
65.3M
IPO Year
2012
2017

Fundamental Metrics

Financial Performance
Metric
SAMG
RNTX
Price
$10.18
$0.87
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$10.00
AVG Volume (30 Days)
56.4K
446.0K
Earning Date
05-01-2026
05-15-2026
Dividend Yield
6.36%
N/A
EPS Growth
N/A
44.16
EPS
0.05
N/A
Revenue
$91,358,000.00
N/A
Revenue This Year
$8.99
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$203.40
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.57
$0.69
52 Week High
$16.56
$2.18

Technical Indicators

Market Signals
Indicator
SAMG
RNTX
Relative Strength Index (RSI) 47.51 57.58
Support Level $9.69 $0.85
Resistance Level $10.63 $0.88
Average True Range (ATR) 0.29 0.06
MACD 0.01 0.01
Stochastic Oscillator 46.46 84.53

Price Performance

Historical Comparison
SAMG
RNTX

About SAMG Silvercrest Asset Management Group Inc.

Silvercrest Asset Management Group Inc is a wealth management firm focused on providing financial advisory and related family office services to ultra-high net-worth individuals and institutional investors. It advises clients on traditional investment strategies focused on equities, fixed income, and cash, as well as non-traditional investment strategies including hedge funds, private equity funds, real estate, and commodities. The firm offers a full suite of complementary and customized family office services for families seeking comprehensive oversight of their financial affairs. The company derives revenues from Managed accounts, Silvercrest funds, Tax and family office services, and Fund administration. The firm generates the majority of its revenue from Managed Accounts.

About RNTX Rein Therapeutics Inc.

Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.

Share on Social Networks: